Berger Financial Group Inc Has $6.86 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Berger Financial Group Inc grew its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,975 shares of the company’s stock after buying an additional 747 shares during the period. Johnson & Johnson makes up approximately 1.0% of Berger Financial Group Inc’s holdings, making the stock its 23rd biggest position. Berger Financial Group Inc’s holdings in Johnson & Johnson were worth $6,857,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Price T Rowe Associates Inc. MD increased its stake in shares of Johnson & Johnson by 18.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. Legal & General Group Plc increased its stake in shares of Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after purchasing an additional 421,779 shares during the period. FMR LLC increased its stake in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Johnson & Johnson by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock worth $1,333,545,000 after purchasing an additional 24,505 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the company’s stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders have sold 300,750 shares of company stock valued at $52,311,677 in the last three months. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.3 %

JNJ stock opened at $173.43 on Friday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The firm has a market cap of $453.43 billion, a P/E ratio of 24.15, a P/E/G ratio of 3.29 and a beta of 0.56. The business’s 50 day moving average is $176.32 and its 200-day moving average is $171.51. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.60 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on JNJ shares. Barclays started coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Atlantic Securities lowered their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Morgan Stanley lowered their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Finally, Sanford C. Bernstein lowered their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $182.42.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.